Cerebral palsy, in its moderate and severe forms, is a chronic, disabling disease whose management involves long and arduous programs of therapy. Improvement is slow and the rate of progress often discouraging. Any drug that would facilitate the rate of improvement or enhance the efficacy of a training program would be a most welcome and valuable adjutant to therapy.
It should be emphasized at the outset that a drug can never be a substitute for training in this condition but at best can afford a degree of relaxation or relief of tension that might in some way result in greater benefits and more rapid results from other forms of therapy.
Many drugs have been employed in the treatment of cerebral palsy. These include the sedative drugs, such as phenobarbital and alcohol, the antiepileptic drugs, such as diphenylhydantoin (dilantin®) and trimethadione (tridione®), drugs of the nightshade family, such as scopolamine and
PERLSTEIN MA, BARNETT HE. NEOSTIGMINE THERAPY IN CEREBRAL PALSYA Critical Evaluation. JAMA. 1950;142(6):403–407. doi:10.1001/jama.1950.02910240021005
Customize your JAMA Network experience by selecting one or more topics from the list below.